A review of the proteasome inhibitor bortezomib in multiple myeloma

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 6, 2004, Pages 1321-1331

  Richardson, Paul G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bortezomib; Cell adhesion mediated drug resistence; Dexamethasone; Multiple myeloma; NF B; Proteasome inhibitor; Ubiquitin proteasome pathway

Indexed keywords

ANTIEMETIC AGENT; BETA 2 MICROGLOBULIN; BLEOMYCIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; HEMOGLOBIN; IDARUBICIN; IFOSFAMIDE; IMATINIB; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE; VINDESINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; FATIGUE; HUMAN; HYPOKALEMIA; HYPONATREMIA; IN VITRO STUDY; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOMA; MALAISE; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; REVIEW; SENSORY NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; DEXAMETHASONE; HUMANS; MULTIENZYME COMPLEXES; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 3142570867     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.6.1321     Document Type: Review

References (92)

1. Cancer Facts & Figures 2003. American Cancer Society, Atlanta (2003).
2. Cancer Facts & Figures for African Americans 2003-2004. American Cancer Society, Atlanta (2003).
3. RAJKUMAR SV, GERTZ MA, KYLE RA, GREIPP PR: Current therapy for multiple myeloma. Mayo Clin. Proc. (2002) 778:813-822.
4. ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. (1996) 3352:91-97.
5. CHILD JA, MORGAN GJ, DAVIES FE et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. (2003) 34819:1875-1883.
6. HUSSEIN MA: Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist (2002) 7(Suppl. 1):20-29.
7. KUMAR A, LOUGHRAN T, ALSINA M, DURIE BG, DJULBEGOVIC B: Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. (2003) 45:293-304.
8. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 1001:57-70.
9. KING RW, DESHAIES RJ, PETERS JM, KIRSCHNER MW: How proteolysis drives the cell cycle. Science (1996) 274(5293):1652-1659.
10. ALMOND JB, COHEN GM: The proteasome: a novel target for cancer chemotherapy. Leukemia (2002) 164:433-443.
11. ADAMS J: Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. (2001) 286:613-619.
12. ADAMS J, PALOMBELLA VJ, ELLIOTT PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs (2000) 182:109-121.
13. ELLIOTT PJ, ROSS JS: The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. (2001) 1165:637-646.
14. CIECHANOVER A: The ubiquitin-proteasome proteolytic pathway. Cell (1994) 791:13-21.
15. ROCK KL, GRAMM C, ROTHSTEIN L et al.: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 785:761-771.
16. HERSHKO A, CIECHANOVER A: The ubiquitin system for protein degradation. Ann. Rev. Biochem. (1992) 61:761-807.
17. BAUMEISTER W, WALZ J, ZUHL F, SEEMULLER E: The proteasome: paradigm of a self-compartmentalizing protease. Cell (1998) 923:367-380.
18. GUZMAN ML, SWIDERSKI CF, HOWARD DS et al.: Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA (2002) 9925:16220-16225.
19. AN B, GOLDFARB RH, SIMAN R, DOU QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. (1998) 512:1062-1075.
20. BERENSON JR, MA HM, VESCIO R: The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Oncol. (2001) 286:626-633.
21. DELIC J, MASDEHORS P, OMURA S et al.: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br. J. Cancer (1998) 777:1103-1107.
22. GUZMAN ML, NEERING SJ, UPCHURCH D et al.: Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 988:2301-2307.
23. HIDESHIMA T, RICHARDSON P, CHAUHAN D et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 617:3071-3076.
24. KUDO Y, TAKATA T, OGAWA I et al.: p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. (2000) 63:916-923.
25. MASDEHORS P, MERLE-BERAL H, MAGDELENAT H, DELIC J: Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk. Lymphoma (2000) 38(5-6):499-504.
26. ORLOWSKI RZ, ESWARA JR, LAFOND-WALKER A et al.: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer.Res. (1998) 5819:4342-4348.
27. MICHALEK MT, GRANT EP, GRAMM C, GOLDBERG AL, ROCK KL: A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature (1993) 363(6429):552-554.
28. PALOMBELLA VJ, RANDO OJ, GOLDBERG AL, MANIATIS T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 785:773-785.
29. READ MA, NEISH AS, LUSCINSKAS FW et al.: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity (1995) 25:493-506.
30. BALDIN V, CANS C, KNIBIEHLER M, DUCOMMUN B: Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem. (1997) 272;52:32731-32734.
31. SCHEFFNER M, HUIBREGTSE JM, HOWLEY PM: Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad Sci. USA (1994) 9119:8797-8801.
32. LATRES E, CHIAUR DS, PAGANO M: The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene (1999) 184:849-854.
33. TSURUMI C, ISHIDA N, TAMURA T et al.: Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol. Cell Biol. (1995) 1510:5682-5687.
34. GROSS-MESILATY S, REINSTEIN E, BERCOVICH B et al.: Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Natl. Acad. Sci. USA (1998) 9514:8058-8063.
35. YANG Y, FANG S, JENSEN JP, WEISSMAN AM, ASHWELL JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 288(5467):874-877.
36. PALOMBELLA VJ, CONNER EM, FUSELER JW et al.: Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. US4 (1998) 9526:15671-15676.
37. CHEN C, EDELSTEIN LC, GELINAS C: The Rel/NF-kappaB family directly activates expression of die apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. (2000) 208:2687-2695.
38. BALDWIN AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Investig. (2001) 1073:241-246.
39. ALKALAY I, YARON A, HATZUBAI A et al.: Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA (1995) 9223:10599-10603.
40. SPENCER E, JIANG J, CHEN ZJ: Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. (1999) 133:284-294.
41. WINSTON JT, STRACK P, BEER-ROMERO P et al.: The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. (1999) 133:270-283.
42. MARTINELLI G, TOSI P, OTTAVIANI E, SOVERINI S, TURA S: Molecular therapy for multiple myeloma. Haematologica (2001) 869:908-917.
43. ANDERSON KC: Novel biologically based therapies for myeloma. Cancer J. (2001) 7(Suppl. 1):S19-S23.
44. LICHTENSTEIN A, TU Y, FADY C, VESCIO R, BERENSON J: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol. (1995) 1622:248-255.
45. HARDIN J, MACLEOD S, GRIGORIEVA I et al.: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood (1994) 849:3063-3070.
46. OGAWA M, NISHIURA T, ORITANI K et al.: Cytokines prevent dexamethasone-induced apoprosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. (2000) 6015:4262-4269.
47. OGATA A, CHAUHAN D, TEOH G et al.: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. (1997) 1595:2212-2221.
48. URASHIMA M, TEOH G, CHAUHAN D et al.: Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood (1997) 901:279-289.
49. UCHIYAMA H, BARUT BA, MOHRBACHER AF, CHAUHAN D, ANDERSON KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 8212:3712-3720.
50. CHAUHAN D, UCHIYAMA H, AKBARALI Y et al.: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 873:1104-1112.
51. HIDESHIMA T, CHAUHAN D, SCHLOSSMAN R, RICHARDSON P, ANDERSON KC: The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 2033:4519-4527.
52. DAMIANO JS, CRESS AE, HAZLEHURST LA, SHTIL AA, DALTON WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 935:1658-1667.
53. SHAIN KH, LANDOWSKI TH, DALTON WS: The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr. Opin. Oncol. (2000) 126:557-563.
54. DAMIANO JS, DALTON WS: Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma (2000) 38(1-2):71-81.
55. SETHI T, RINTOUL RC, MOORE SM et al.: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. (1999) 56:662-668.
56. ADAMS J, BEHNKE M, CHEN S et al.: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. (1998) 84:333-338.
57. DICK LR, CRUIKSHANK AA, GRENIER L et al.: Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clastolactacystin beta-lactone. J. Biol. Chem. (1996) 271;13:7273-7276.
58. MENG L, KWOK BH, SIN N, CREWS CM: Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. (1999) 5912:2798-2801.
59. KROLL M, ARENZANA-SEISDEDOS F, BACHELERIE F et al.: The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem. Biol. (1999) 610:689-698.
60. NAM S, SMITH DM, DOU QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. (2001) 276;16:13322-13330.
61. FURET P, IMBACH P, FUERST P et al.: Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg. Med. Chem. Lett. (2002) 1210:1331-1334.
62. ALMOND JB, SNOWDEN RT, HUNTER A et al.: Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia (2001) 159:1388-1397.
63. IZBAN KF, ERGIN M, HUANG Q et al.: Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod. Pathol. (2001) 144:297-310.
64. DREXLER HC: Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA (1997) 943:855-860.
65. PAJONK F, PAJONK K, MCBRIDE WH: Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int. J. Radiat. Oncol. Biol. Phys. (2000) 474:1025-1032.
66. SOLIGO D, SERVIDA F, DELIA D et al.: The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol. (2001) 1131:126-135.
67. UCHIYAMA H, BARUT BA, CHAUHAN D, CANNISTRA SA, ANDERSON KC: Characterization of adhesion molecules on human myeloma cell lines. Blood (1992) 809:2306-2314.
68. LANDOWSKI T, DALTON W: Myeloma cell adhesion to fibronectin activates NF-KappaB and induces the expression of genes contributing to cell adhesion mediated drug resistance. Blood (2001) 98:377a (Abstract 1589).
69. ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. (1999) 5911:2615-2622.
70. MITSIADES N, MITSIADES CS, POULAKI V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA (2002) 9922:14374-14379.
71. LEBLANC R, CATLEY LP, HIDESHIMA T et al.: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. (2002) 6217:4996-5000.
72. MITSIADES N, MITSIADES CS, RICHARDSON PG et al.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2003) 1016:2377-2380.
73. MA MH, YANG HH, PARKER K et al.: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. (2003) 93:1136-1144.
74. MITSIADES CS, TREON SP, MITSIADES N et al.: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 983:795-804.
75. PANDIELLA A, CARVAJAL X, TABERA S, MATEO G, SAN MIGUEL J: Inhibition of multiple myeloma proliferation by imatinib mesylate (STI571). Blood (2002) 100:601a (Abstract 2363).
76. HIDESHIMA T, CHAUHAN D, RICHARDSON P et al.: NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. (2002) 277;19:16639-16647.
77. ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 2022:4420-4427.
78. AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 88:2505-2511.
79. RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348;26:2609-2617.
80. BERENSON J, JAGANNATH J, BARLOGIE B et al.: Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc. Am. Soc. Clin. Oncol. (2003) 22:581 (Abstract 2337).
81. MILESHKIN L, BIAGI JJ, MITCHELL P et al.: Multicenter Phase II trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood (2003) 1021:69-77.
82. BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase II study of 169 patients. Blood (2001) 982:492-494.
83. DESIKAN R, BARLOGIE B, SAWYER J et al.: Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood (2000) 9512:4008-4010.
84. JAGANNATH S, BARLOGIE B, BERENSON J et al.: A Phase II multicenter randomized study of the proteasome inhibitor bortezomib (VELCADE™), formerly PS-341) in multiple myeloma (MM) patients (pts) relapsed after front-line therapy. Blood (2002) 100:812a (Abstract 3207).
85. YANG H, SWIFT R, SADLER K et al.: A Phase I/II trial of VELCADE™ and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myelorna (MM). Blood (2003) 102:235a (Abstract 2340).
86. ORLOWSKI RZ, VOORHEES PM, GARCIA RA et al.: Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood (2003) 102:449a.
87. ZANGARI M, BARLOGIE B, JACOBSON J et al.: VTD regimen comprising Velcade (V) + thalidomide (T) and added dex (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) responding after autologous transplant. Blood (2003) 102:236a.
88. O'CONNOR O, WRIGHT J, MOSKOWITZ C et al.: Promising activity of the proteasome inhibitor bortezomib (Velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Blood (2003) 102:636a (Abstract #2346).
89. GOYA, HART S, PRO B et al.: Report of a Phase II study of proteasome inhibitor bortezomib (VELCADE™) in patients with relapsed or refractory indolent and aggressive lymphomas. Blood (2003) 102:180a (Abstract #627).
90. ASSOULINE S, BELCH A, SEHN L et al.: A Phase II study of bortezomib in patients with mantle cell lymphoma. Blood (2003) 102:902a.
91. RICHARDSON P, BARLOGIE B, BERENSON J et al.: Prognostic factors for response parameters and overall survival in patients with multiple myeloma (MM) following treatment with bortezomib. Blood (2003) 102:446a (Abstract 2338).
92. RICHARDSON P, BARLOGIE B, BERENSON J et al.: Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc. Am. Soc. Clin. Oncl. (2003) 22:581 (Abstract 2338).